Twist Bioscience reports Q3 revenue of $118.4M, beating estimates, but GAAP EPS misses by $0.08.
Twist Bioscience posted a Q3 GAAP loss per share of $0.56, missing estimates by $0.08. Revenue reached $118.4 million, up 23.2% year-over-year and exceeding expectations by $3.86 million.
The company’s revenue growth outpaced consensus, while earnings fell short of projections. Analysts had anticipated $444.69 million for fiscal 2026, but Twist now expects revenue between $456 million and $457 million.
No immediate market reaction was disclosed in the release.